人3型副流感病毒嵌合FHN糖蛋白联合佐剂疫苗诱导保护性免疫
研究在哺乳动物细胞中表达纯化了由融合蛋白N端胞外域与血凝素-神经氨酸酶蛋白连接而成的嵌合FHN糖蛋白及可分泌的F、HN蛋白,以poly(I:C)与多聚磷腙偶联的先天防御调节肽(TriAdj)为佐剂免疫小鼠和棉鼠,FHN/TriAdj诱导的全身中和抗体水平显著高于F+HN/TriAdj,鼻内接种可诱导肺部黏膜IgA和血清中和抗体,棉鼠攻毒后各接种途径均未检出病毒,仓鼠中亦诱导保护性免疫。
要点
- FHN/TriAdj免疫小鼠和棉鼠的全身中和抗体水平显著高于F+HN/TriAdj。
- 鼻内接种FHN/TriAdj可诱导肺部黏膜IgA产生和血清中和抗体。
- 棉鼠无论经何种途径接种FHN/TriAdj,PIV3攻毒后均未检出病毒。
核心结论
- FHN蛋白联合TriAdj佐剂具有开发安全有效PIV3疫苗的潜力。
研究设计与样本
- 在哺乳动物细胞中表达纯化嵌合FHN糖蛋白及可分泌的F和HN蛋白,以TriAdj为佐剂肌内或鼻内免疫小鼠、棉鼠和仓鼠。
主要发现
- 小鼠和棉鼠中FHN/TriAdj组全身病毒中和抗体水平显著高于F+HN/TriAdj组。
- 鼻内接种FHN/TriAdj可在肺部产生黏膜IgA并在血清中产生病毒中和抗体。
- 棉鼠经FHN/TriAdj免疫后,无论肌内还是鼻内途径,PIV3攻毒均未检出病毒。
- FHN/TriAdj在仓鼠中亦诱导针对PIV3的保护性免疫。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human parainfluenza virus type 3 (PIV3) is a major cause of lower respiratory disease i.e. bronchitis, bronchiolitis or pneumonia, in infants and young children. Presently there is no licensed vaccine against PIV3. To produce an effective subunit vaccine, a chimeric FHN glycoprotein consisting of the N-terminal ectodomain of the fusion (F) protein linked to the haemagglutinin-neuraminidase (HN) protein without transmembrane domain, and secreted forms of the individual F and HN glycoproteins, were expressed in mammalian cells and purified. Mice and cotton rats were immunized intramuscularly (IM) with FHN or both F and HN proteins (F + HN), formulated with poly(I:C) and an innate defense regulator peptide in polyphosphazene (TriAdj). Significantly higher levels of systemic virus-neutralizing antibodies were observed in mice and cotton rats immunized with FHN/TriAdj when compared to animals immunized with the combination of F and HN proteins (F + HN/TriAdj). As PIV3 is a pneumotropic virus, another goal is to produce an effective mucosal subunit vaccine. Intranasal (IN) administration with FHN/TriAdj resulted in mucosal IgA production in the lung and virus neutralizing antibodies in the sera. After PIV3 challenge no virus was detected in cotton rats immunized with FHN/TriAdj regardless of the route of delivery. Protective immunity against PIV3 was also induced by FHN/TriAdj in hamsters. In conclusion, the FHN protein formulated with TriAdj has potential for development of a safe and effective vaccine against PIV3.
引用
- Garg R, Brownlie R, Latimer L, et al. Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity. Vaccine. 2017. PMID: 29153777. doi:10.1016/j.vaccine.2017.10.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。